SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection.

Le Doare, K; Allen, L; Kampmann, B; Heath, PT; Taylor, S; Hesseling, AC; Gorringe, A; Jones, CE (2015) Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine, 33 (5). pp. 621-627. ISSN 1873-2518 https://doi.org/10.1016/j.vaccine.2014.12.025
SGUL Authors: Heath, Paul Trafford Le Doare, Kirsty Jones, Christine Elizabeth Mehring-Le Doare, Kirsty Elaine Kay

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (685kB) | Preview

Abstract

BACKGROUND: HIV-exposed uninfected infants have increased infection risk and mortality compared to HIV-unexposed infants. HIV-exposed infants may be at increased risk of invasive GBS disease due to reduced maternal antibody against GBS. METHODS: We quantified antibodies that bind to the surface of whole Group B Streptococcus (GBS) of serotypes Ia, Ib, II, III and V using novel flow cytometry assays in South African HIV-infected and non-infected mothers and their uninfected infants. Antibody-mediated complement C3b/iC3b deposition onto GBS of these serotypes was also quantified by a novel flow cytometry assay. RESULTS: Geometric mean concentration (GMC) of both surface-binding anti-GBS antibody and antibody-mediated complement deposition onto GBS were reduced in HIV-infected women (n=46) compared to HIV-uninfected women (n=58) for ST1a (surface-binding: 19.3 vs 29.3; p=0.003; complement deposition: 2.9 vs 5.3 SU/mL; p=0.003), STIb (24.9 vs 47.6; p=0.003; 2.6 vs 4.9 SU/mL; p=0.003), STII (19.8 vs 50.0; p=0.001; 3.1 vs 6.2 SU/mL; p=0.001), STIII (27.8 vs 60.1; p=0.001; 2.8 vs 5.3 SU/mL; p=0.001) and STV (121.9 vs 185.6 SU/mL; p<0.001) and in their infants for STIa (complement deposition 9.4 vs 27.0 SU/mL; p=0.02), STIb (13.4 vs 24.5 SU/mL; p=0.02), STII (14.6 vs 42.7 SU/mL; p=0.03), STIII (26.6 vs 62.7 SU/mL; p=0.03) and STV (90.4 vs 165.8 SU/mL; p=0.04). Median transplacental transfer of antibody from HIV-infected women to their infants was reduced compared to HIV-uninfected women for GBS serotypes II (0.42 [IQR 0.22-0.59] vs 1.0 SU/mL [0.42-1.66]; p<0.001), III (0.54 [0.31-1.03] vs 0.95 SU/mL [0.42-3.05], p=0.05) and V (0.51 [0.28-0.79] vs 0.75 SU/mL [0.26-2.9], p=0.04). The differences between infants remained significant at 16 weeks of age. CONCLUSIONS: Maternal HIV infection was associated with lower anti-GBS surface binding antibody concentration and antibody-mediated C3b/iC3b deposition onto GBS bacteria of serotypes Ia, Ib, II, III and V. This may render these infants more susceptible to early and late onset GBS disease.

Item Type: Article
Additional Information: Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Antibody, Group B Streptococcus, HIV, HIV-exposed-uninfected infants, Immunity, Antibodies, Bacterial, Cohort Studies, Complement System Proteins, Female, Flow Cytometry, HIV Infections, Humans, Immunity, Maternally-Acquired, Infant, Infant, Newborn, Male, Pregnancy, Pregnancy Complications, Infectious, South Africa, Streptococcus agalactiae, Humans, Streptococcus agalactiae, Pregnancy Complications, Infectious, HIV Infections, Antibodies, Bacterial, Flow Cytometry, Cohort Studies, Immunity, Maternally-Acquired, Pregnancy, Infant, Infant, Newborn, South Africa, Complement System Proteins, Female, Male, Antibody, Group B Streptococcus, HIV-exposed-uninfected infants, HIV, Immunity, 06 Biological Sciences, 07 Agricultural And Veterinary Sciences, 11 Medical And Health Sciences, Virology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Vaccine
ISSN: 1873-2518
Language: eng
Dates:
DateEvent
29 January 2015Published
24 December 2014Published Online
12 December 2014Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MC_EX_MR/K011944/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MC_UP_A900_1122Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
KLD2013Wellcome Trusthttp://dx.doi.org/10.13039/100004440
01012013Royal College of Physicianshttp://dx.doi.org/10.13039/501100000395
PubMed ID: 25543061
Web of Science ID: WOS:000349503700007
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111333
Publisher's version: https://doi.org/10.1016/j.vaccine.2014.12.025

Actions (login required)

Edit Item Edit Item